Regeneron And Sanofi To Present Phase 3 LIBERTY-CUPID Study C Study Data Evaluating Dupixent; Says Dupixent Reduced Itch And Hive Activity From Baseline, 41% Of Patients Achieved Well-Controlled Disease Status
Regeneron And Sanofi To Present Phase 3 LIBERTY-CUPID Study C Study Data Evaluating Dupixent; Says Dupixent Reduced Itch And Hive Activity From Baseline, 41% Of Patients Achieved Well-Controlled Disease Status
Regeneron和賽諾菲安萬特將發佈第3期LIBERTY-CUPID研究C研究數據，評估Dupixent；稱Dupixent將瘙癢和蕁麻疹活動從基線降低，41%的患者實現了疾病狀態得到良好控制
Regeneron And Sanofi To Present Phase 3 LIBERTY-CUPID Study C Study Data Evaluating Dupixent; Says Dupixent Reduced Itch And Hive Activity From Baseline, 41% Of Patients Achieved Well-Controlled Disease Status
Regeneron和賽諾菲安萬特將發佈第3期LIBERTY-CUPID研究C研究數據，評估Dupixent；稱Dupixent將瘙癢和蕁麻疹活動從基線降低，41%的患者實現了疾病狀態得到良好控制
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間